Bacterial Endotoxin Tests (BET)

BET detects and quantifies bacterial endotoxins (LPS) from Gram-negative bacteria—potent pyrogens that can cause fever and severe reactions if present in parenterals. BET is required for parenteral drugs and, where applicable, medical devices (tested via extracts) to ensure patient safety.

Legacy (Pyrogen test in rabbits, RPT) – historic in vivo test for total pyrogens; slow/variable, being phased out in many regions (replaced by in vitro tests such as MAT for non-endotoxin pyrogens).

Established pharmacopoeial standard: LAL – Limulus amebocyte lysate–based BET with three compendial formats: gel-clot (qualitative), turbidimetric (kinetic/endpoint), chromogenic (kinetic/endpoint). LAL remains the global benchmark in USP <85> / Ph. Eur. 2.6.14.

Emerging/recognized alternative: recombinant Factor C (rFC) – Animal-free reagent that triggers the same endotoxin-specific step (Factor C activation) without Factor G (avoids β-glucan cross-reactivity). Ph. Eur. has now integrated rFC (Method G, fluorimetric) into 2.6.14; USP recognizes recombinant endotoxin tests via alternative-method pathways (see <1085> guidance and validation per <1223>).

LAL methods (gel-clot / turbidimetric / chromogenic): Endotoxin activates Factor C → Factor B → proclotting enzyme, leading to clot formation (gel-clot) or cleavage of chromogenic/turbidimetric substrates that are read spectrophotometrically. Classic LAL may contain Factor G, which can be triggered by (1→3)-β-D-glucans (see “Limitations”).

rFC methods (fluorimetric): Recombinant Factor C is activated by endotoxin and directly cleaves a fluorogenic substrate; there is no Factor G arm, so β-glucans do not cause false positives. (Some platforms are cartridge-based; readouts are typically EU/mL.)

Plate reader-based LAL (kinetic): Build a standard curve (log–log), interpolate unknowns, and verify positive product control (PPC) spike recovery, typically 50–200%, to prove no inhibition/enhancement. Ensure testing at or below the MVD (maximum valid dilution) calculated from the product’s endotoxin limit.

Cartridge systems (e.g., Endosafe PTS): Pre-calibrated curve per cartridge lot; the instrument reports EU/mL and Pass/Fail, including automatic PPC recovery checks. (Vendors implement compendial acceptance logic.)

Universal rule: The result must be ≤ the product’s endotoxin limit and the method suitability (spike recovery/controls) must pass.

High sensitivity (down to ~0.001 EU/mL depending on kit/setup).

High specificity for endotoxin (Factor C–based).

Globally recognized in major pharmacopoeias for parenterals; device expectations referenced in USP <161> and AAMI ST72.

Inhibition/enhancement by excipients: address via method suitability and dilution to MVD.

β-Glucan interference (LAL Factor G):  use glucan-blocking buffers, endotoxin-specific LAL, or rFC.

Lot-to-lot variability (biologic reagents): qualify each lot; rFC may reduce variability.

Scope: LAL/rFC detect endotoxin only, not non-endotoxin pyrogens (where MAT is appropriate).

Method suitability / I&E testing: Demonstrate acceptable PPC recovery (often 50–200%) at the intended dilution(s).

Range & linearity (for kinetic methods) over the working interval.

Reagent/lot qualification and control standard endotoxin (CSE/RSE) traceability.

Alternative methods: Validate per USP <1223> and follow USP <1085> guidance when implementing rFC or novel platforms.

The Bacterial Endotoxins Test (BET) is standardized globally across the major pharmacopeias (USP <85>, Ph. Eur. 2.6.14, JP 4.01), ensuring harmonized acceptance criteria and assay performance. Endotoxin quantitation is referenced against control standard endotoxin (CSE) calibrated to the USP or WHO reference standard endotoxin (RSE), establishing traceability across laboratories. Each new lot of lysate or recombinant Factor C reagent must be qualified with these reference materials, and method suitability testing (spike recovery 50–200%) is mandatory to confirm that the product matrix does not interfere. This reliance on shared reference standards and harmonized methods ensures consistency and comparability of endotoxin results across sites, products, and regulatory submissions.

• mAbs & Proteins: Standard application. High protein concentrations can sometimes cause interference, often requiring significant dilution of the sample.
• Cell & Gene Therapies: A critical safety test. The complex nature of these products (containing cells, vectors, complex buffers) can make them particularly prone to inhibition/enhancement effects, requiring careful method development.
• Oligonucleotides: These products can sometimes be inhibitory to the LAL assay, necessitating robust validation of the testing method.
• Medical Devices: Extracts from medical devices are tested to ensure the device surface is free from significant endotoxin contamination.